GeNeuro (DB:GEM) - Aandelenkoers, Nieuws & Analyse

GEM Overzicht aandelen

GeNeuro SA, een biofarmaceutisch bedrijf in een klinische fase, ontwikkelt geneesmiddelen voor de behandeling van neurodegeneratieve en auto-immuunziekten.

Over het bedrijf

GEM fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

Risicoanalyse

Negatief eigen vermogen

Heeft een omzet van minder dan 1 miljoen USD ( €0 )

De winst is de afgelopen 5 jaar met 8.6% per jaar gedaald

Heeft geen betekenisvolle marktkapitalisatie ( €2M )

+ 2 meer risico's

GeNeuro SA Concurrenten

bioXXmed

XTRA:T5O

€1.4m

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€24.4m

2invest

XTRA:2INV

€59.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor GeNeuro
Historische aandelenkoersen
Huidige aandelenkoers	€0.053
52 Week Hoogtepunt	€2.42
52 Week Laag	€0.039
Bèta	0.37
11 maand verandering	8.61%
3 maanden verandering	22.12%
1 Jaar Verandering	-95.23%
33 jaar verandering	-98.65%
5 jaar verandering	-98.54%
Verandering sinds IPO	-99.55%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	GEM	DE Biotechs	DE Markt
7D	-4.3%	-1.5%	0.1%
1Y	-95.2%	-11.7%	19.6%

Rendement versus industrie: GEM presteerde slechter dan de German Biotechs -sector, die het afgelopen jaar een rendement van -13.6 % opleverde.

Rendement versus markt: GEM presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 13.3 % opleverde.

Prijsvolatiliteit

Is GEM's price volatile compared to industry and market?
GEM volatility
GEM Average Weekly Movement	42.2%
Biotechs Industry Average Movement	6.2%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.3%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van GEM is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van GEM is het afgelopen jaar gestegen van 32% naar 39%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2006	17	Jesus Martin-Garcia	www.geneuro.com

GeNeuro SA, een biofarmaceutisch bedrijf in een klinische fase, ontwikkelt geneesmiddelen voor de behandeling van neurodegeneratieve en auto-immuunziekten. De belangrijkste therapeutische kandidaat van het bedrijf is temelimab, een monoklonaal antilichaam dat een pathogeen eiwit van de HERV-W-familie neutraliseert, diabetes type 1 behandelt en chronische inflammatoire demyeliniserende polyneuropathie behandelt. Het ontwikkelt ook GNK301.

GeNeuro SA Samenvatting

Hoe verhouden de winst en inkomsten van GeNeuro zich tot de beurswaarde?
GEM fundamentele statistieken
Marktkapitalisatie	€2.20m
Inkomsten(TTM)	-€14.76m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.1x

Koers/Winstverhouding

Is GEM overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
GEM resultatenrekening (TTM)
Inkomsten	€0
Kosten van inkomsten	€0
Brutowinst	€0
Overige uitgaven	€14.76m
Inkomsten	-€14.76m

Laatst gerapporteerde inkomsten

Dec 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.50
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	-93.4%

Hoe presteerde GEM op de lange termijn?

Bekijk historische prestaties en vergelijking

GEM Overzicht aandelen

Beloningen

Risicoanalyse

GeNeuro SA Concurrenten

XTRA:T5O

€1.4m

XTRA:CNW

€6.5m

XTRA:MDG1

€24.4m

XTRA:2INV

€59.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

GeNeuro Announces Results of the Gnc-501 Study in Post-Covid-19 Syndrome

GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024

New minor risk - Financial data availability

Geneuro SA Announces Appointments of Board of Directors

GeNeuro SA has completed a Follow-on Equity Offering in the amount of €4.900246 million.

Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications

Recent updates

GeNeuro Announces Results of the Gnc-501 Study in Post-Covid-19 Syndrome

GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024

New minor risk - Financial data availability

Geneuro SA Announces Appointments of Board of Directors

GeNeuro SA has completed a Follow-on Equity Offering in the amount of €4.900246 million.

Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications

New major risk - Revenue and earnings growth

Forecast to breakeven in 2024

GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024

GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024

New major risk - Negative shareholders equity

GeNeuro SA Announces Recent Study Demonstrates the Strong Link Between SARS-CoV-2 Infection and HERV-W Activation in Hospitalized Psychotic Patients

New major risk - Share price stability

GeNeuro SA to Report First Half, 2023 Results on Sep 29, 2023

Insufficient new directors

GeNeuro SA, Annual General Meeting, Jun 14, 2023

Insufficient new directors

GeNeuro SA Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-Covid Assessing Temelimab

Geneuro’S Protect-Ms Phase 2 Trial Data, Presented At the Ectrims 2022 Congress in Amsterdam, Confirms Synergistic Neuroprotective Potential of Temelimab in Ms

GeNeuro Will Present Phase IIb Safety and Efficacy Data on Temelimab from its ProTEct-MS Study at the 38thCongress of the European Committee for Treatment and Research in Multiple Sclerosis

Geneuro Is Granted Authorization by the Swiss Health Authority to Initiate A Phase II Study Evaluating Temelimab in Patients with Severe Neuropsychiatric Post-Covid Syndromes

Insufficient new directors

GeNeuro SA, Annual General Meeting, May 31, 2022

GeNeuro and Fondamental Foundation Announce the First Results of the Collaboration for the Development of Diagnostic and Therapeutic Options for Patients with Post-Covid Neuropsychiatric Syndromes

GeNeuro Announces the Completion of Its ProTEct-MS Study and Confirms the March Timeline for Top-line Results

Geneuro Sa unveils Additional Results from the Preclinical Research Program in Amyotrophic Lateral Sclerosis (Als) Developed in Partnership with the National Institute of Neurological Disorders and Stroke

Geneuro Receives EUR 6.4 Million in Funding from the Swiss Government for the Development of Temelimab Against Long-Covid

GeNeuro Announces First Patient Having Finished the ProTEct-MS Study at the Karolinska Institutet’s Academic Specialist Center Has Entered the Study Extension

Insufficient new directors

GeNeuro Announces the Publication in Multiple Sclerosis of Results From CHANGE-MS and ANGEL-MS Studies

Geneuro Presents Data Supporting Pathogenic Role of an Endogenous Retroviral Protein (HERV-W ENV) in Post-Covid Neuropsychiatric Syndrome

GeNeuro SA Announces Independent Drug Safety Monitoring Board (Dsmb) Has Concluded the Phase 2 Trial of Temelimab in Ms Patients

GeNeuro Completes Patient Recruitment in Temelimab Phase 2 Multiple Sclerosis Trial at the Karolinska Institutet’s Academic Specialist Center (ASC)

New 90-day high: €3.85

New 90-day low: €2.57

New 90-day low: €2.94

New 90-day low: €3.01

GeNeuro SA Announces Management Changes

GeNeuro SA to Report First Half, 2020 Results on Sep 29, 2020

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

GeNeuro SA Samenvatting

0.0x

-0.1x

Inkomsten en omzet